Abstract:Current evidence suggests that DEP domain containing 1 (DEPDC1) has an important effect on non-small-cell lung cancer (NSCLC). However, the diagnostic value and the regulatory function within NSCLC are largely unclear. This work utilized publicly available databases and in vitro experiments for exploring, DEPDC1 expression, clinical features, diagnostic significance and latent molecular mechanism within NSCLC. According to our results, DEPDC1 was remarkably upregulated in the tissues of NSCLC patients compared with non-carcinoma tissues, linked with gender, stage, T classification and N classification based on TCGA data and associated with smoking status and stage according to GEO datasets. Meanwhile, the summary receiver operating characteristic (sROC) curve analysis result showed that DEPDC1 had a high diagnostic value in NSCLC (AUC = 0.96, 95% CI: 0.94-0.98; diagnostic odds ratio = 99.08, 95%CI: 31.91-307.65; sensitivity = 0.89, 95%CI: 0.81-0.94; specificity = 0.92, 95%CI: 0.86-0.96; positive predictive value = 0.94, 95%CI: 0.89-0.98; negative predictive value = 0.78, 95%CI: 0.67-0.90; positive likelihood ratio = 11.77, 95%CI: 6.11-22.68; and negative likelihood ratio = 0.12, 95%CI: 0.06-0.22). Subsequently, quantitative real-time PCR (qRT-PCR) and western blotting indicated that DEPDC1 was high expressed in NSCLC cells. According to the in vitro MTS and apoptotic assays, downregulated DEPDC1 expression targeting P53 signaling pathway inhibited the proliferation of NSCLC cells while promoting apoptosis of NSCLC cells. Moreover, DEPDC1 was significantly correlated with immune cell infiltrating levels in NSCLC based on TCGA data, which were primarily associated with T cells CD4 memory activated, macrophages M1, B cells memory, mast cells resting, T cells regulatory, monocytes, and T cells CD4 memory resting. Compared with the group with high expression of DEPDC1, the group with low expression level had higher scores for immune checkpoint inhibitors (ICIs) treatment. GSEA confirmed that DEPDC1 was involved in gene expression and tumor-related signaling pathways. Finally, DEPDC1 and its associated immune-related genes were shown to be enriched in 'receptor ligand activity', 'external side of plasma membrane', 'regulation of innate immune response', and 'Epstein-Barr virus infection' pathways. The present study demonstrates that DEPDC1 may contribute to NSCLC tumorigenesis and can be applied as the biomarker for diagnosis and immunology.

Significance of DEK Overexpression for the Prognostic Evaluation of Non-Small Cell Lung Carcinoma.

High Expression of Oncoprotein DEK Predicts Poor Prognosis of Small Cell Lung Cancer.

Expression of DEK in Pancreatic Cancer and Its Correlation with Clinicopathological Features and Prognosis

Prognostic Significance of DEK Protein Expression in Patients with Squamous Cell Lung Carcinoma

MDK Protein Overexpression Correlates with the Malignant Status and Prognosis of Non-small Cell Lung Cancer

Dek over Expression As an Independent Biomarker for Poor Prognosis in Colorectal Cancer

Prognostic Role of DEK in Human Solid Tumors: a Meta-Analysis

DEK Protein Expression in the Prognosis of Patients with Lung Adenocarcinoma

Overexpression of DEK is an Indicator of Poor Prognosis in Patients with Gastric Adenocarcinoma.

DEK overexpression is correlated with the clinical features of breast cancer.

DEK Protein Overexpression Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

The Role of DEK Protein in Hepatocellular Carcinoma for Progression and Prognosis

High Expression of DEK Predicts Poor Prognosis of Gastric Adenocarcinoma.

Oncogene DEK is Highly Expressed in Lung Cancerous Tissues and Positively Regulates Cell Proliferation As Well As Invasion.

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer

Mechanisms Underlying Cancer Growth and Apoptosis by DEK Overexpression in Colorectal Cancer.

Clinicopathological Significance of DEK Overexpression in Serous Ovarian Tumors

DEK Overexpression in Uterine Cervical Cancers

Correlation between the expression and pathobiological characteristics of DEK protein in gastric cancer

Inhibition of DEK Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia Cells